Faculty Opinions recommendation of Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958301.793464607 ◽

2012 ◽

Author(s):

Nancy Lin ◽

Ines Vaz-Luis

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Advanced Breast Cancer ◽

Bone Metastases ◽

Advanced Breast ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Download Full-text

Faculty Opinions recommendation of Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958301.793464163 ◽

2012 ◽

Author(s):

Arun Bhaskar

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Advanced Breast Cancer ◽

Bone Metastases ◽

Advanced Breast ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Download Full-text

Faculty Opinions recommendation of Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958301.793463926 ◽

2012 ◽

Author(s):

Rajesh Gupta

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Advanced Breast Cancer ◽

Bone Metastases ◽

Advanced Breast ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Download Full-text

Faculty Opinions recommendation of Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958301.793496812 ◽

2014 ◽

Author(s):

Mellar Davis

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Advanced Breast Cancer ◽

Bone Metastases ◽

Advanced Breast ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Download Full-text

Pain Outcomes in Patients With Advanced Breast Cancer and Bone Metastases: Results From a Randomized, Double-Blind Study of Denosumab and Zoledronic Acid

Breast Diseases A Year Book Quarterly ◽

10.1016/j.breastdis.2013.07.037 ◽

2013 ◽

Vol 24 (3) ◽

pp. 220-221

Author(s):

C.L. Shapiro

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Advanced Breast Cancer ◽

Bone Metastases ◽

Advanced Breast ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Download Full-text

Faculty Opinions recommendation of Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.7216956.8792054 ◽

2011 ◽

Author(s):

Carmelo Bengala

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Advanced Breast Cancer ◽

Bone Metastases ◽

Advanced Breast ◽

Blind Study ◽

Double Blind Study ◽

Download Full-text

Faculty Opinions recommendation of Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.7216956.7465054 ◽

2010 ◽

Author(s):

Larry Suva

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Advanced Breast Cancer ◽

Bone Metastases ◽

Advanced Breast ◽

Blind Study ◽

Double Blind Study ◽

Download Full-text

Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study

European Journal of Cancer ◽

10.1016/s0959-8049(99)80705-9 ◽

1999 ◽

Vol 35 ◽

pp. S84 ◽

Author(s):

E. Bajetta ◽

L.Y. Dirix ◽

L.E. Fein ◽

S.E. Jones ◽

J. Cervek ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Survival Advantage ◽

Advanced Breast ◽

Blind Study ◽

Megestrol Acetate ◽

Phase Iii ◽

Double Blind Study ◽

Download Full-text

Faculty Opinions recommendation of Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.9875966.793494170 ◽

2014 ◽

Author(s):

Thomas Flaig

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Castration Resistant

Download Full-text

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study

Yearbook of Urology ◽

10.1016/j.yuro.2011.06.011 ◽

2011 ◽

Vol 2011 ◽

pp. 74-75

Author(s):

A.S. Kibel

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Castration Resistant

Download Full-text

Re: Denosumab Versus Zoledronic Acid for Treatment of Bone Metastases in Men With Castration-Resistant Prostate Cancer: A Randomised, Double-Blind Study

The Journal of Urology ◽

10.1016/j.juro.2011.08.108 ◽

2011 ◽

Vol 186 (6) ◽

pp. 2254-2255 ◽

Author(s):

Patrick C. Walsh

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Castration Resistant

Download Full-text